BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI) Files An 8-K Results of Operations and Financial Condition

BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 and Item 9.01 of this Form 8-K is being furnished and shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 2.02 and Item 9.01 of this Form 8-K shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended.

Item 2.02. Results of Operations and Financial Condition.
Story continues below

On February 14, 2019, Bioanalytical Systems, Inc. issued a press release announcing results for the three months of fiscal 2019 ended December 31, 2018. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.
99.1 Bioanalytical Systems, Inc. press release, issued February 14, 2019.

EX-99.1 2 tv513726_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1       FOR MORE INFORMATION: Company Contact:    Jill Blumhoff    Chief Financial Officer &   Vice President of Finance    Phone:  765.497.8381    [email protected]    BASi Reports Revenue Growth in First Quarter of Fiscal 2019   WEST LAFAYETTE,…
To view the full exhibit click here


Bioanalytical Systems, Inc. (BASi) is a contract research organization (CRO) providing drug discovery and development services and analytical instruments. The Company operates through two segments: contract research services and research products. Its contract research services segment provides research and development support on a contract basis directly to pharmaceutical companies. Its research products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. Its Culex family of robotic automated dose delivery, blood and other biofluids sampling and physiological parameters measurement systems enable researchers to determine pharmacokinetic/pharmacodynamic (PK/PD) profiles of drugs in large and small animal models. The Company’s bioanalytical services group supports research, preclinical and clinical programs.

An ad to help with our costs